Following U.S. Stocks were among the “Top Gainers” during Monday’s trade: Biocept Inc (NASDAQ:BIOC), RMG Networks Holding Corporation (NASDAQ:RMGN), Inventergy Global Inc (NASDAQ:INVT), Advaxis, Inc (NASDAQ:ADXS)
Their insights are depicted underneath:
RMG Networks Holding Corporation (NASDAQ:RMGN)’s stocks skyrocketed 68.93%, and closed at $1.74.
Through Marketwired, RMG Networks Holding Corporation (RMGN), a leading provider of technology-driven visual communications solutions, declared preliminary financial results for its fourth quarter and full year ended December 31, 2014.
Fourth quarter 2014 adjusted proceed is predictable to be about $18.6 million and full year 2014 adjusted proceed is predictable to be about $61.8 million. In addition, the corporation anticipates fourth quarter 2014 adjusted EBITDA to improve sequentially over the third quarter of 2014.
Both of the corporation’s business units are predictable to show strong sequential fourth quarter adjusted proceed growth. In its Enterprise and Media businesses, fourth quarter adjusted proceed is predictable to be $13.1 million and $5.5 million, respectively. These preliminary financial results are subject to completion of the corporation’s customary year-end closing and review procedures and audit by the corporation’s independent registered public accounting firm.
Robert Michelson, Chief Executive Officer, commented, “We executed well in the fourth quarter and our results are encouraging as we expect strong sequential growth in both adjusted proceed and adjusted EBITDA. In addition, we continued to successfully implement the planned initiatives that we expect will further establish the platform for long-term success.”
“Since the third quarter, we have brought to market the first three products in our ‘Six New Products in Six Months’ initiative, strengthening our product portfolio with unique solutions,” continued Mr. Michelson. “In addition, our sales team has significantly bolstered the number of seven-figure deals in our pipeline. This steadfast focus on product innovation, global coordination and sales team productivity has begun to drive the momentum that we believe will deliver accelerated growth starting later this year.”
RMG Networks will release its full financial results for the fourth quarter and full-year 2014 before the market opens on Thursday, March 19, 2015. Administration will host a conference call to talk about these results on Thursday, March 19, 2015 at 9 a.m. ET.
RMG Networks (NASDAQ: RMGN) assists brands and organizations communicate more effectively using location-based video networks. The corporation builds enterprise video networks that empower organizations to visualize critical data to better run their business.
Inventergy Global Inc (NASDAQ:INVT), raised 42.86%, and closed at $0.800.
Through Marketwired, Inventergy Global, Inc. (INVT), declared that it has launched a collaborative new Mobile User Device licensing initiative for its 3G/LTE mobility patent portfolio, providing standardized rates and terms to mobile equipment manufacturers. The portfolio comprises Standards Essential Patents (SEPs); that is, patents covering technologies that must be used to comply with a technical standard.
Inventergy attained over 500 patent assets in Mobile Broadband (3G-LTE) Technologies from Panasonic, a global leader in telecommunications and consumer electronics.
Inventergy’s Mobile User Device Portfolio comprises at least 34 mobile broadband patent families, comprising of nearly 350 patents having claims directed to mobile end user devices, such as mobile phones, tablets, PCs, modems and mobile hotspots. Inventergy believes at least 15 patent families in this portfolio, comprising of at least 189 patents, contain SEPs covering 3G and LTE communications functionality in end user devices. Such User Device SEPs would generally be subject to fair, reasonable, and non-discriminatory (FRAND) licensing which Inventergy is honoring through its Mobile User Device licensing program.
According to the International Data Corporation (IDC), the worldwide market for mobile handsets is projected to reach over 1 billion worldwide units sold in 2015 and nearly 10 billion cumulatively over the next five years.
Inventergy Global, Inc. is Silicon Valley-based intellectual property corporation dedicated to identifying, acquiring and licensing the patented technologies of market-noteworthy technology leaders. Led by IP industry pioneer and veteran Joe Beyers, the Corporation leverages decades of corporate experience, market and technology expertise, and industry connections to assist Fortune 500 companies in leveraging the value of their innovations to achieve greater returns.
Biocept Inc (NASDAQ:BIOC), enhanced 8.71%, and closed at $3.37.
Through GLOBE NEWSWIRE, Biocept, Inc. (BIOC), a molecular oncology diagnostics corporation specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), declared its financial results for the fourth quarter and year ended December 31, 2014.
Fourth Quarter and Recent Highlights:
- Strengthened the Corporation’s product line of non-small cell lung cancer (NSCLC) diagnostics through multiple product launches, counting:
- The launch of SelectorTM, Biocept’s novel blood-based diagnostic platform for detecting cancer mutations for non-small cell lung cancer patients
- Addition of a test for ROS1 in CTCs to assist physicians identify patients who may respond to commercially-accessible NSCLC treatments
- Partnershipwith Insight Genetics to develop an improved diagnostic for the expression and mutations of ALK, a major therapeutic target in the treatment of NSCLC
- Signed a payor contract with America’s Choice Provider Network (ACPN), a Preferred Provider Organization (PPO), to provide ACPN’s about 19 million participants access to Biocept’s products using a blood sample (liquid biopsy)
- Improved medical expertise with the appointment of Veena Singh, MD, FCAP, FACMG as Senior Medical Director
- Expanded worldwide protection of microfluidic channel with a granted patent in South Korea
- Accomplished a follow-on offering of $10 million in gross proceeds to support the expansion of its growth strategy and bring new assays to market since the closing of the follow-on offering, about $7 million has been received from the exercise of warrants comprised of in the transaction.
- Declared data from Dana Farber Cancer Institute where Biocept’s liquid biopsy was used to identify a subset of patients who were Her2 positive utilizing a blood sample despite a previous Her2 negative tissue biopsy
- Declared results of a study at Columbia University demonstrating a high concordance of Biocept’s blood-based product to tissue biopsy results in patients with primary and metastatic breast cancer when testing for Hormone Receptors in order to qualify patients for personalized therapies
- Expanded molecular diagnostic development expertise with the appointment of Jason Poole, Ph.D. as Senior Director, Molecular Assay Development.
Biocept, Inc., headquartered in San Diego, California, is a commercial-stage oncology diagnostics corporation focused on providing information on patients’ tumors to physicians using its proprietary technology platform to assist improve individual patient treatment.
Advaxis, Inc (NASDAQ:ADXS), rose 7.65%, and closed at $12.81.
Through GLOBE NEWSWIRE, on March 5, Advaxis, Inc. (ADXS), a clinical-stage biotechnology corporation developing cancer immunotherapies, declared recently that Daniel J. O’Connor, President and Chief Executive Officer of Advaxis, will present at the 27th Annual ROTH Conference being held March 8-11, 2015, at the Ritz-Carlton Hotel in Laguna Niguel, CA.
Advaxis is a clinical-stage biotechnology corporation developing multiple cancer immunotherapies based on its proprietary Lm-LLO platform technology. The Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth.
